Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Wednesday

Cue Biopharma (NASDAQ:CUE) is anticipated to announce its earnings results on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $1.70 million for the quarter.

Cue Biopharma Trading Up 4.6 %

NASDAQ CUE opened at $1.03 on Tuesday. The firm has a market capitalization of $65.25 million, a PE ratio of -1.14 and a beta of 1.88. The business’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.17. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05. Cue Biopharma has a 12 month low of $0.45 and a 12 month high of $2.26.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.